Published in J Infect Dis on January 01, 1972
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Vaccines and cell-mediated immunity. Bacteriol Rev (1974) 5.42
Comparative immunogenicity of heat-killed and living oral Salmonella vaccines. Infect Immun (1972) 2.72
Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis (2014) 2.15
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol (2007) 2.11
Microbiological hazards of household toilets: droplet production and the fate of residual organisms. Appl Microbiol (1975) 1.84
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun (1999) 1.80
Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol (1991) 1.73
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection. Infect Immun (1993) 1.62
Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med (1995) 1.54
Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect Immun (1991) 1.47
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun (2000) 1.44
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun (1994) 1.43
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Dose-response relationships for environmentally mediated infectious disease transmission models. PLoS Comput Biol (2017) 1.37
Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun (1991) 1.34
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun (1996) 1.32
Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun (1999) 1.23
Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses. Infect Immun (1975) 1.09
The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies. Philos Trans R Soc Lond B Biol Sci (2000) 1.06
Alternative hand contamination technique to compare the activities of antimicrobial and nonantimicrobial soaps under different test conditions. Appl Environ Microbiol (2008) 1.05
Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect Immun (1998) 1.04
Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. Infect Immun (2002) 1.03
Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei. J Clin Microbiol (1992) 1.02
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect Immun (2001) 1.01
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun (2001) 1.00
Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species. Infect Immun (1984) 0.98
Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect Immun (1994) 0.98
Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect Immun (1996) 0.97
Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid. Infect Immun (1982) 0.91
Epidemic spread of Shigella sonnei shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz). J Clin Microbiol (1994) 0.90
Role of antigen form in development of mucosal immunoglobin A response to Shigella flexneri Antigens. Infect Immun (1981) 0.88
Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine (2012) 0.84
Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. PLoS One (2015) 0.84
Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun (2011) 0.84
Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin Immunol (2013) 0.82
Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T. World J Gastroenterol (2006) 0.81
Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm. Clin Diagn Lab Immunol (1995) 0.81
Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide. Infect Immun (1996) 0.79
Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release. PLoS One (2014) 0.79
Bacterial colitis. Clin Colon Rectal Surg (2007) 0.78
Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics. PLoS One (2013) 0.77
Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects. Clin Vaccine Immunol (2016) 0.76
EPITHELIAL CELL PENETRATION AS AN ESSENTIAL STEP IN THE PATHOGENESIS OF BACILLARY DYSENTERY. J Bacteriol (1964) 19.60
Involvement of a plasmid in the invasive ability of Shigella flexneri. Infect Immun (1982) 13.55
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (1981) 9.67
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science (1984) 7.94
Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med (1976) 6.52
Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun (1983) 6.43
Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect Immun (1981) 6.40
Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis (1974) 6.38
Plasmid-associated enterotoxin production in a strain of Escherichia coli isolated from humans. Infect Immun (1972) 6.21
Detection and characterization of colonization factor of enterotoxigenic Escherichia coli isolated from adults with diarrhea. Infect Immun (1978) 5.71
Protein synthesis in HeLa or Henle 407 cells infected with Shigella dysenteriae 1, Shigella flexneri 2a, or Salmonella typhimurium W118. Infect Immun (1981) 5.39
Typhoid fever: pathogenesis and immunologic control. N Engl J Med (1970) 4.95
Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet (1983) 4.89
Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen. Infect Immun (1980) 4.87
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli. Infect Immun (1983) 4.82
Shigellosis due to Shigella dysenteriae. 1. Relative importance of mucosal invasion versus toxin production in pathogenesis. J Infect Dis (1972) 4.60
Hemagglutination patterns of enterotoxigenic and enteropathogenic Escherichia coli determined with human, bovine, chicken, and guinea pig erythrocytes in the presence and absence of mannose. Infect Immun (1979) 4.60
Experimental bacillary dysentery. An electron microscopic study of the response of the intestinal mucosa to bacterial invasion. Am J Pathol (1965) 4.42
Non-cholera vibrio infections in the United States. Clinical, epidemiologic, and laboratory features. Ann Intern Med (1978) 4.28
Invasion of HeLa cells by Salmonella typhimurium: a model for study of invasiveness of Salmonella. J Infect Dis (1973) 4.22
Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) (1969) 4.20
Plaque formation by virulent Shigella flexneri. Infect Immun (1985) 4.16
Fecal leukocytes in diarrheal illness. Ann Intern Med (1972) 3.89
Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun (1986) 3.87
Infantile diarrhea produced by heat-stable enterotoxigenic Escherichia coli. N Engl J Med (1976) 3.82
Identification and antigenic characterization of virulence-associated, plasmid-coded proteins of Shigella spp. and enteroinvasive Escherichia coli. Infect Immun (1985) 3.78
Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA (1999) 3.77
Handwashing to prevent diarrhea in day-care centers. Am J Epidemiol (1981) 3.75
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
A case of cholera in Texas, 1973. Am J Epidemiol (1974) 3.71
Role of solid media when used in conjunction with the BACTEC system for mycobacterial isolation and identification. J Clin Microbiol (1991) 3.60
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969. J Infect Dis (1970) 3.41
Virulence of Shigella flexneri hybrids expressing Escherichia coli somatic antigens. Infect Immun (1972) 3.33
Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol (1980) 3.31
Inhibition of in vitro protein synthesis by Shigella dysenteriae 1 toxin. Biochem Biophys Res Commun (1976) 3.30
Intracellular spread of Shigella flexneri associated with the kcpA locus and a 140-kilodalton protein. Infect Immun (1989) 3.24
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis (1998) 3.18
Inactivation of Norwalk virus in drinking water by chlorine. Appl Environ Microbiol (1985) 3.12
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis (2001) 3.08
Patterns of loss of enterotoxigenicity by Escherichia coli isolated from adults with diarrhea: suggestive evidence for an interrelationship with serotype. Infect Immun (1977) 3.04
Biological properties of Shigella flexneri 2A toxin and its serological relationship to Shigella dysenteriae 1 toxin. Infect Immun (1977) 2.94
A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli. J Infect Dis (1985) 2.94
Comparative susceptibility of latin american and united states students to enteric pathogens. N Engl J Med (1976) 2.94
Molecular characterization of plasmids from virulent and spontaneously occurring avirulent colonial variants of Shigella flexneri. Infect Immun (1979) 2.93
Impact in the United States of the Shiga dysentery pandemic of Central America and Mexico: a review of surveillance data through 1972. J Infect Dis (1974) 2.91
Scombroid fish poisoning. Outbreak traced to commercially canned tuna fish. JAMA (1974) 2.84
Epidemic diarrhea at Crater Lake from enterotoxigenic Escherichia coli. A large waterborne outbreak. Ann Intern Med (1977) 2.80
Pathogenesis of salmonellosis. Studies of fluid secretion, mucosal invasion, and morphologic reaction in the rabbit ileum. J Clin Invest (1973) 2.78
Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen. Infect Immun (1978) 2.78
Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect (2010) 2.77
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med (1982) 2.71
Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrob Agents Chemother (1976) 2.71
Virulence of three distinct Cryptosporidium parvum isolates for healthy adults. J Infect Dis (1999) 2.65
Role of Escherichia coli colonisation factor antigen in acute diarrhoea. Lancet (1978) 2.65
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med (1970) 2.63
Fluorescent-antibody and histological study of vaccinated and control monkeys challenged with Shigella flexneri. J Bacteriol (1966) 2.60
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Adverse effect of lomotil therapy in shigellosis. JAMA (1973) 2.57
Exerimental acute colitis in the Rhesus monkey following peroral infection with Shigella flexneri. An electron microscope study. Am J Pathol (1968) 2.53
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Cholera on Guam, 1974: epidemiologic findings and isolation of non-toxinogenic strains. Am J Epidemiol (1977) 2.46
Virulence factors of enterotoxigenic Escherichia coli. J Infect Dis (1977) 2.45
Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect Control (1981) 2.43
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
The isolation and characterization of a Norwalk virus-specific cDNA. J Clin Invest (1991) 2.42
Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev (1966) 2.42
Plasmid-mediated invasiveness of "Shigella-like" Escherichia coli. Ann Microbiol (Paris) (1982) 2.38
International outbreak of Salmonella Eastbourne infection traced to contaminated chocolate. Lancet (1975) 2.32